Douglas M. Willis

Array ( [id] => 17837687 [patent_doc_number] => 20220274992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => SUBSTITUTED (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL) AMINO COMPOUNDS USEFUL AS JAK 1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/638074 [patent_app_country] => US [patent_app_date] => 2020-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673046 [patent_doc_number] => 20210061809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/002045 [patent_app_country] => US [patent_app_date] => 2020-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17002045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102367 [patent_doc_number] => 11542242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Substituted piperazines as selective HDAC1,2 inhibitors [patent_app_type] => utility [patent_app_number] => 16/997025 [patent_app_country] => US [patent_app_date] => 2020-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29832 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18000175 [patent_doc_number] => 11501284 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Substituted pyrazines as inhibitors of BTK, and mutants thereof [patent_app_type] => utility [patent_app_number] => 16/996516 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24080 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703095 [patent_doc_number] => 10953008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor [patent_app_type] => utility [patent_app_number] => 16/996314 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 20410 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621447 [patent_doc_number] => 20210040100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => JAK INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/988253 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770833 [patent_doc_number] => 10981921 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Fragment synthesis of substituted cyclic peptides [patent_app_type] => utility [patent_app_number] => 16/985096 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11549 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16655945 [patent_doc_number] => 20210052581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => USE OF TADALAFIL AS PROTEIN ARGININE METHYLTRANSFERASE (PRMT5) INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/945907 [patent_app_country] => US [patent_app_date] => 2020-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16945907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16940998 [patent_doc_number] => 11053219 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-06 [patent_title] => Substituted pyridines as TYK2 inhibitors [patent_app_type] => utility [patent_app_number] => 16/938183 [patent_app_country] => US [patent_app_date] => 2020-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86944 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16938183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20432511 [patent_doc_number] => 12502379 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => Ponesimod for avoiding worsening of fatigue-related symptoms in multiple sclerosis patients [patent_app_type] => utility [patent_app_number] => 17/628387 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 49 [patent_no_of_words] => 11206 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17628387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18296734 [patent_doc_number] => 20230106420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/628402 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17628402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452489 [patent_doc_number] => 20200361915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/932627 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421818 [patent_doc_number] => 20200347016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS [patent_app_type] => utility [patent_app_number] => 16/929573 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483510 [patent_doc_number] => 20230210807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => USE OF BENZOATE COMPOUND IN TREATMENT OF SARS-COV-2 INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/793959 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17220674 [patent_doc_number] => 11173157 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-16 [patent_title] => Substituted pyrimidines containing acidic groups as TLR7 modulators [patent_app_type] => utility [patent_app_number] => 16/930214 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39651 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16930214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17452978 [patent_doc_number] => 11267823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity [patent_app_type] => utility [patent_app_number] => 16/924390 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41907 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16924390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398696 [patent_doc_number] => 20200339554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS [patent_app_type] => utility [patent_app_number] => 16/924157 [patent_app_country] => US [patent_app_date] => 2020-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16924157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389521 [patent_doc_number] => 20200330462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION [patent_app_type] => utility [patent_app_number] => 16/918084 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40417 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16918084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16360928 [patent_doc_number] => 20200317679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => NOVEL MTOR INHIBITOR COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/907154 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525195 [patent_doc_number] => 20200399275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/902499 [patent_app_country] => US [patent_app_date] => 2020-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 255 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902499 [rel_patent_id] =>[rel_patent_doc_number] =>)